AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$36.90 USD
-1.04 (-2.74%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $36.90 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$36.90 USD
-1.04 (-2.74%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $36.90 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth C Momentum A VGM
Zacks News
AMN Healthcare Services (AMN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $99.34, moving +1.03% from the previous trading session.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Henry Schein (HSIC) Global Dental Arm Rebounds Amid Cost Woes
by Zacks Equity Research
Henry Schein's (HSIC) widespread network and channel mix along with favorable long-term trends in the dental business look encouraging.
Hologic (HOLX) New Products Aid Growth, Margin Pressure Stays
by Zacks Equity Research
Hologic's (HOLX) core molecular diagnostics franchise is growing driven by strong uptake in newer assays such as vaginitis panel and menu within the virology product line.
PerkinElmer's (PKI) Arm Introduces Two CE-Marked Assays
by Zacks Equity Research
PerkinElmer's (PKI) company launches two CE-marked antibody tests that can support the analysis of the immune response to COVID-19.
Bruker (BRKR) Debuts Module on Ultima Multiphoton Microscopes
by Zacks Equity Research
Bruker's (BRKR) NeuraLight 3D Ultra module offers revolutionary 3D holographic photostimulation to support neuroscience and optogenetics research applications.
Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
West Pharmaceutical's (WST) Syringe System to Improve Outcome
by Zacks Equity Research
West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
How Much Upside is Left in AMN Healthcare (AMN)? Wall Street Analysts Think 32%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 32% in AMN Healthcare (AMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at the Animal Health segment.
Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout
by Zacks Equity Research
According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.
3 Reasons Why Growth Investors Shouldn't Overlook AMN Healthcare (AMN)
by Zacks Equity Research
AMN Healthcare (AMN) could produce exceptional returns because of its solid growth attributes.
ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany
by Zacks Equity Research
ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.
BD's (BDX) Latest Collaboration to Enhance Patient Care
by Zacks Equity Research
BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.
Here's Why You Should Hold Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.
Here's Why You Should Hold on to Ecolab (ECL) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
by Zacks Equity Research
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex's (TFX) better-than-expected results and strong growth within the vascular business.
Align (ALGN) Hurt by Dental Practice Closures, FX Headwind
by Zacks Equity Research
Align (ALGN) competes with products similar to Invisalign Technology, such as the products from Ormco Orthodontics, a division of Sybron Dental Specialties.
Here's Why You Should Retain Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
CONMED (CNMD) to Expand Orthopedic Portfolio With Buyout
by Zacks Equity Research
CONMED's (CNMD) completion of In2Bones Global buyout will expand its orthopedic portfolio.
Humana (HUM) to Offer Home Care Model to Virginia's MA Members
by Zacks Equity Research
Humana (HUM) expands the customer reach of its unit's value-based home care model to Virginia, with an aim to offer better in-home care services to the state's Medicare Advantage members.